CN101338322B - 高分子聚合物构建的新型基因载体及制备方法 - Google Patents
高分子聚合物构建的新型基因载体及制备方法 Download PDFInfo
- Publication number
- CN101338322B CN101338322B CN2008100487816A CN200810048781A CN101338322B CN 101338322 B CN101338322 B CN 101338322B CN 2008100487816 A CN2008100487816 A CN 2008100487816A CN 200810048781 A CN200810048781 A CN 200810048781A CN 101338322 B CN101338322 B CN 101338322B
- Authority
- CN
- China
- Prior art keywords
- cationic
- liposome
- novel gene
- preparation
- gene vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 239000013598 vector Substances 0.000 title claims abstract description 32
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 31
- 229920000642 polymer Polymers 0.000 title claims abstract description 23
- 239000002502 liposome Substances 0.000 claims abstract description 36
- 239000002245 particle Substances 0.000 claims abstract description 32
- 239000000203 mixture Substances 0.000 claims description 41
- 239000000725 suspension Substances 0.000 claims description 32
- 229920006317 cationic polymer Polymers 0.000 claims description 31
- 108020004414 DNA Proteins 0.000 claims description 26
- 238000002156 mixing Methods 0.000 claims description 23
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 16
- 125000004423 acyloxy group Chemical group 0.000 claims description 14
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- 238000013016 damping Methods 0.000 claims description 13
- 150000002148 esters Chemical class 0.000 claims description 13
- 239000012530 fluid Substances 0.000 claims description 13
- 230000004048 modification Effects 0.000 claims description 13
- 238000012986 modification Methods 0.000 claims description 13
- -1 polymine Polymers 0.000 claims description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- 229920002643 polyglutamic acid Polymers 0.000 claims description 10
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 9
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 9
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 235000012000 cholesterol Nutrition 0.000 claims description 8
- 238000005352 clarification Methods 0.000 claims description 8
- 150000004985 diamines Chemical class 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 8
- 229920001661 Chitosan Polymers 0.000 claims description 7
- 238000000265 homogenisation Methods 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 239000000523 sample Substances 0.000 claims description 7
- 230000002269 spontaneous effect Effects 0.000 claims description 7
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 6
- 108010039918 Polylysine Proteins 0.000 claims description 6
- 150000004702 methyl esters Chemical class 0.000 claims description 6
- 229920000656 polylysine Polymers 0.000 claims description 6
- 229920000333 poly(propyleneimine) Polymers 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 238000002604 ultrasonography Methods 0.000 claims description 2
- OUGMXUSYDAVRMZ-UHFFFAOYSA-N azane;dimethyl sulfate Chemical compound N.COS(=O)(=O)OC OUGMXUSYDAVRMZ-UHFFFAOYSA-N 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 26
- 238000001890 transfection Methods 0.000 abstract description 24
- 150000001768 cations Chemical class 0.000 abstract description 9
- 108020004459 Small interfering RNA Proteins 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 4
- 230000001404 mediated effect Effects 0.000 abstract description 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 239000002609 medium Substances 0.000 abstract 1
- 239000002574 poison Substances 0.000 abstract 1
- 231100000614 poison Toxicity 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 66
- 235000015097 nutrients Nutrition 0.000 description 30
- 239000013612 plasmid Substances 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- 230000003115 biocidal effect Effects 0.000 description 20
- 150000003904 phospholipids Chemical class 0.000 description 19
- 239000000126 substance Substances 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 16
- 241000700605 Viruses Species 0.000 description 13
- 239000012096 transfection reagent Substances 0.000 description 13
- 150000005846 sugar alcohols Polymers 0.000 description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 229920005654 Sephadex Polymers 0.000 description 10
- 239000012507 Sephadex™ Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 239000002105 nanoparticle Substances 0.000 description 7
- 229920002521 macromolecule Polymers 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 5
- HCXJFMDOHDNDCC-UHFFFAOYSA-N 5-$l^{1}-oxidanyl-3,4-dihydropyrrol-2-one Chemical group O=C1CCC(=O)[N]1 HCXJFMDOHDNDCC-UHFFFAOYSA-N 0.000 description 5
- 108091092584 GDNA Proteins 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 description 5
- 238000006062 fragmentation reaction Methods 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 239000006194 liquid suspension Substances 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 238000005204 segregation Methods 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- NYDLOCKCVISJKK-WRBBJXAJSA-N [3-(dimethylamino)-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC NYDLOCKCVISJKK-WRBBJXAJSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010061188 Haematotoxicity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 101150099105 alien gene Proteins 0.000 description 1
- 239000012237 artificial material Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004033 diameter control Methods 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000004335 litholrubine BK Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
项目 | 指标 |
粒子直径 纳米≤ | 30 |
PH值范围 | 5.5-6.5 |
RNa se,unit/mL ≤ | 4 |
DNa se,unit/mL ≤ | 2 |
项目 | 指标 |
菌落总数,cfu/ML ≤ | 1000 |
大肠菌群,MPN/100mL ≤ | 60 |
内毒素,EU/1mL ≤ | 1.0 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100487816A CN101338322B (zh) | 2008-08-13 | 2008-08-13 | 高分子聚合物构建的新型基因载体及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100487816A CN101338322B (zh) | 2008-08-13 | 2008-08-13 | 高分子聚合物构建的新型基因载体及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101338322A CN101338322A (zh) | 2009-01-07 |
CN101338322B true CN101338322B (zh) | 2010-06-02 |
Family
ID=40212493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100487816A Active CN101338322B (zh) | 2008-08-13 | 2008-08-13 | 高分子聚合物构建的新型基因载体及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101338322B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2729127B1 (en) * | 2011-07-04 | 2018-05-02 | Statens Serum Institut | Methods for producing liposomes |
CN109663149A (zh) * | 2017-10-17 | 2019-04-23 | 天津大学 | 非病毒类载体投递MicroRNA与骨粉的复合材料及其制备方法 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102144973A (zh) * | 2011-03-31 | 2011-08-10 | 中国药科大学 | 一种优化的siRNA阳离子脂质体的处方组成 |
CN102775602B (zh) * | 2012-08-15 | 2014-02-19 | 中国科学院长春应用化学研究所 | 一种聚乙烯亚胺-聚赖氨酸共聚物及其制备方法 |
CN103030813B (zh) * | 2012-12-21 | 2015-08-05 | 深圳先进技术研究院 | 一种壳聚糖接枝聚乙烯亚胺非病毒转基因载体的制备方法 |
CN109402177A (zh) * | 2018-11-07 | 2019-03-01 | 上海健康医学院 | 一种适用于外源基因转染的纳米载体材料及其制备方法 |
CN112704742A (zh) * | 2019-10-24 | 2021-04-27 | 华东理工大学 | 一种用于恶性肿瘤治疗的包载质粒的阳离子脂质体复合物 |
CN110917121B (zh) * | 2019-12-11 | 2021-01-05 | 四川大学 | 一种apd杂化纳米***及其构建方法和应用 |
CN112641952A (zh) * | 2020-12-25 | 2021-04-13 | 中国科学院长春应用化学研究所 | 基因传递载体、含该基因传递载体的基因传递***及其药物组合物 |
CN112960985B (zh) * | 2021-01-22 | 2023-06-16 | 佛山市山有海科技有限公司 | 一种液体解胶增强剂及其制备方法 |
-
2008
- 2008-08-13 CN CN2008100487816A patent/CN101338322B/zh active Active
Non-Patent Citations (6)
Title |
---|
Adam Golda ET AL.Small Poly- L -Lysines Improve Cationic Lipid-MediatedGeneTransfer in Vascular Cells in vitro and in vivo.Journal of Vascular Research第44卷 第4期.2007,第44卷(第4期),第273-282页. |
Adam Golda ET AL.Small Poly- L-Lysines Improve Cationic Lipid-MediatedGeneTransfer in Vascular Cells in vitro and in vivo.Journal of Vascular Research第44卷 第4期.2007,第44卷(第4期),第273-282页. * |
Luis Brito ET AL.Poly (Β-amino ester) and Cationic Phospholipid-BasedLipopolyplexes for Gene Delivery andTransfectioninHumanAortic Endothelial and Smooth MuscleCells.Biomacromolecules第9卷 第4期.2008,第9卷(第4期),第1179-1187页. |
Luis Brito ET AL.Poly (Β-amino ester) and Cationic Phospholipid-BasedLipopolyplexes for Gene Delivery andTransfectioninHumanAortic Endothelial and Smooth MuscleCells.Biomacromolecules第9卷 第4期.2008,第9卷(第4期),第1179-1187页. * |
Pasi Lampela ET AL.Synergism in gene delivery by small PEIs and threedifferentnonviral vectors.International Journal of Pharmaceutics第270卷 第1-2期.2004,第270卷(第1-2期),第175-184页. |
Pasi Lampela ET AL.Synergism in gene delivery by small PEIs and threedifferentnonviral vectors.International Journal of Pharmaceutics第270卷 第1-2期.2004,第270卷(第1-2期),第175-184页. * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2729127B1 (en) * | 2011-07-04 | 2018-05-02 | Statens Serum Institut | Methods for producing liposomes |
CN109663149A (zh) * | 2017-10-17 | 2019-04-23 | 天津大学 | 非病毒类载体投递MicroRNA与骨粉的复合材料及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101338322A (zh) | 2009-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101338322B (zh) | 高分子聚合物构建的新型基因载体及制备方法 | |
DE69906977T2 (de) | In liposomen verkapselte nukleinsäurekomplexe | |
Nguyen et al. | Functionalized, biodegradable hydrogels for control over sustained and localized siRNA delivery to incorporated and surrounding cells | |
US10583084B2 (en) | Liposomal formulations for delivery of nucleic acids | |
CN100549044C (zh) | 可生物降解的交联聚乙烯亚胺及其应用 | |
Orefice | Development of new strategies using extracellular vesicles loaded with exogenous nucleic acid | |
CN105801668B (zh) | 一种寡聚精氨酸修饰的磷脂与其组装的纳米粒及制备方法和应用 | |
CN102234658A (zh) | 靶向性季铵盐类阳离子高分子脂质基因载体、制备方法及应用 | |
EP0905254A2 (de) | Mit biologisch verträglichen niedermolekularen Polyethyleniminen assoziierte DNA-Vektor | |
Tong et al. | Preparation of protamine cationic nanobubbles and experimental study of their physical properties and in vivo contrast enhancement | |
WO2023186128A2 (zh) | 混合单元、混合器、微流控芯片、混合装置 | |
CN102250348B (zh) | 一种聚乙烯亚胺衍生物及其作为基因传递的载体 | |
CN108395531A (zh) | 一种包裹纳米金颗粒的两性离子和***啉修饰的聚酰胺-胺树状大分子的制备方法 | |
CN109054377A (zh) | 一种树枝状聚酰胺胺结合氧化石墨烯新型复合材料及制备方法与应用 | |
CN106188537A (zh) | 一种修饰的聚乙烯亚胺化合物及其制备方法和应用 | |
CN108096189A (zh) | 一种脂质体纳米颗粒及其药物组合物和应用 | |
CN107353408A (zh) | 一种主客体自组装作用构建表面氨基的核‑壳超结构树状大分子的方法 | |
CN107867677A (zh) | 一维磷酸钙纳米/微米材料及其制备方法和应用 | |
CN104974343A (zh) | 改性聚乙烯亚胺及其在制备基因转染载体试剂中的应用 | |
CN103725713B (zh) | 聚乙二醇化壳聚糖在作为核酸载体中的应用 | |
CN109576206A (zh) | 一种基于联合法分离外泌体的方法 | |
Zhang et al. | Polycation nanostructured lipid carrier, a novel nonviral vector constructed with triolein for efficient gene delivery | |
JP2021521861A (ja) | 耐性細胞型をトランスフェクトするための組成物 | |
CN102813942A (zh) | 脂质超声微泡介导的腺相关病毒基因转染制剂及制备工艺 | |
CN102517332A (zh) | Egf修饰的pamam自组装转基因组合物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: MAZHU TECHNOLOGY CO., LTD. Effective date: 20141106 Owner name: SHANGHAI MAZHU BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: MINXING SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD., WUHAN CITY Effective date: 20141106 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 430070 WUHAN, HUBEI PROVINCE TO: 201203 PUDONG NEW AREA, SHANGHAI |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141106 Address after: 201203. B401-2, No. 456 blue wave road, Shanghai, Pudong New Area Patentee after: Shanghai Manasseh bead Biological Technology Co. Ltd. Address before: 430070 Hubei Province, Wuhan city Hongshan District Luoshi Road No. 441 Singapore Mingju building 3 1-301 Patentee before: Minxing Science and Technology Development Co., Ltd., Wuhan City Patentee before: Mazhu Technology Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG HAICHANG BIOLOGICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: SHANGHAI MAZHU BIOTECHNOLOGY CO., LTD. Effective date: 20150610 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150610 Address after: Green Ting Road Yuhang District Cang Qian street of Hangzhou city Zhejiang province 311121 No. 1 Building No. 3 room 103 Patentee after: WUHAN HUAYAO BIOLOGICAL PHARMACEUTICAL CO., LTD. Address before: 201203. B401-2, No. 456 blue wave road, Shanghai, Pudong New Area Patentee before: Shanghai Manasseh bead Biological Technology Co. Ltd. |
|
CP02 | Change in the address of a patent holder |
Address after: 310000 room 1109, building 2, Wanjing Lake Central West area, Xiasha street, Qiantang new area, Hangzhou, Zhejiang Patentee after: ZHEJIANG HAICHANG BIO-TECH CO.,LTD. Address before: 311121 room 103, building 3, No. 1, Lvting Road, Cangqian street, Yuhang District, Hangzhou City, Zhejiang Province Patentee before: ZHEJIANG HAICHANG BIO-TECH CO.,LTD. |
|
CP02 | Change in the address of a patent holder |